Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Pipeline Pioneers
  • Published:

Pasireotide

Nature Reviews Drug Discovery volume 11, pages 597–598 (2012)Cite this article

Subjects

In April 2012, pasireotide (Signifor; Novartis), a cyclohexapeptide analogue of the hormone somatostatin, was granted marketing authorization by the European Commission for the treatment of Cushing's disease.

Cushing's disease is a rare disorder in which circulating levels of cortisol are chronically high owing to a corticotropin-secreting pituitary adenoma1. It is associated with a range of clinical features including obesity, hypertension, insulin resistance and dyslipidaemia, and patients with uncontrolled disease have increased mortality1.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Pasireotide.

References

  1. Newell-Price, J. et al. Cushing's syndrome. Lancet 367, 1605–1617 (2006).

    Article  CAS  Google Scholar 

  2. Bruns, C. et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146, 707–716 (2002).

    Article  CAS  Google Scholar 

  3. Colao, A. et al. A 12-month Phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 366, 914–924 (2012).

    Article  CAS  Google Scholar 

  4. European Medicines Agency (EMA). European Public Assessment Report. EMA website [online], (2012).

  5. Feelders, R. A. et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N. Engl. J. Med. 362, 1846–1848 (2010).

    Article  CAS  Google Scholar 

  6. Fleseriu, M. et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J. Clin. Endocrinol. Metab. 97, 2039–2049 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Richard A. Feelders is at the Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.,

    Richard A. Feelders

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.,

    Peter Kirkpatrick

Authors
  1. Richard A. Feelders
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Richard A. Feelders, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

Richard. A. Feelders has acted as a consultant for Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feelders, R., Yasothan, U. & Kirkpatrick, P. Pasireotide. Nat Rev Drug Discov 11, 597–598 (2012). https://doi.org/10.1038/nrd3788

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3788

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer